UCSF Navigation Bar

UCSF Departments of Pathology & Laboratory Medicine Home Page

Lab Manual for UCSF Clinical Laboratories

Lab Manual for SFGH

Internal Resources

Click here for more information about laboratory operations and procedures

If you have additional questions regarding this test, please call: 415-353-1667

Search Our Test Menu

ClonoSEQ (Formerly 'ClonoSight')

Item Value
Approval req'd? Yes, for inpatient orders.
Available Stat? No
Test code MOLT
Performed by Adaptive Biotechnologies
Sendout? Yes
Method PCR and next-generation sequencing
Collection Instructions All samples for clonoSEQ testing should be sent to Adaptive Biotechnologies in Seattle, WA.

Due to limited samle stability, collect samples Monday-Friday only and send via FedEx overnight, avoiding holidays. Samples are accepted by Adaptive Biotechnologies Monday through Saturday from 8AM to 5PM PT.

Adaptive Biotechnologies specimen guideline can be downloaded here: http://www.adaptivebiotech.com/sites/default/files/clonoSEQ_Test_Specimen_Requirements.pdf
Container type Lavender top
Amount to Collect
Blood 10 mL
Bone marrow 3 mL
Sample type EDTA anticoagulated blood or bone marrow
Preferred volume
Blood 10 mL
Bone marrow 3 mL
Min. Volume
Blood 10 mL
Bone marrow 3 mL
Processing notes Keep samples at room temperature. Forward to CB at room temperature.
Normal range
Synonyms Molecular Minimal residual disease testing; MRD; ClonoSight; LymphoSight
Stability Room temperature 11 days
Turn around times 7 days for fresh specimens; 14 days for archived specimens
Additional information The previous lab (Sequenta; South San Francisco) that performed the ClonoSight test was purchased by Adaptive Biotechnologies (Seattle) in May of 2015 and is no longer accepting samples. The ClonoSight test has been replaced by the ClonoSeq assay, which is the name of a similar test that Adaptive Biotechnologies offers. These assays have been shown to be highly concordant.

All samples for clonoSEQ testing should be sent to Adaptive Biotechnologies in Seattle, WA.

For patients who were originally evaluated (had malignant clones identified) using Sequenta's ClonoSight assay, additional steps may be required prior to continuing with MRD testing on the Adaptive Biotechnologies clonoSEQ assay. It is imperative that the sendout lab be notified if a patient falls into this category so that they can work with Adaptive to transition the patient's testing to clonoSEQ.
Last Updated 6/23/2017 3:52:44 PM
Entry Number 1566
UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center